Stubbs et al - TMAO and CV Outcomes in EVOLVE_CJASN.pdf

The data demonstrates that baseline levels of TMAO, a circulating compound derived from byproducts of intestinal bacteria, do not predict cardiovascular endpoints in patients with end-stage kidney disease.